首页> 中文期刊> 《蛋白质与细胞 》 >Increasing the safety and efficacy of chimeric antigen receptor T cell therapy

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy

         

摘要

Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment that has recently been undergoing rapid development.However,there are still some major challenges,including precise tumor targeting to avoid off-target or "on-target/off-tumor" toxicity,adequate T cell infiltration and migration to solid tumors and T cell proliferation and persistence across the physical and biochemical barriers of solid tumors.In this review,we focus on the primary challenges and strategies to design safe and effective CAR T cells,including using novel cuffing-edge technologies for CAR and vector designs to increase both the safety and efficacy,further T cell modification to overcome the tumorassociated immune suppression,and using gene editing technologies to generate universal CAR T cells.All these efforts promote the development and evolution of CAR T cell therapy and move toward our ultimate goal-curing cancer with high safety,high efficacy,and low cost.

著录项

  • 来源
    《蛋白质与细胞 》 |2017年第8期|573-589|共17页
  • 作者

    Hua Li; Yangbing Zhao;

  • 作者单位

    Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia,PA 19104-5156, USA;

    Cancer Center, Chengdu Military General Hospital, Chengdu 610083, China;

    Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia,PA 19104-5156, USA;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号